secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001140361-25-018800
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech Q1 net loss $8.5M; Phase 3 VERSATILE-003 trial underway
-------------------------------------------------------------------

- Net loss of $8.5M ($0.21 per share) in Q1 2025 vs $10.6M ($0.30) in Q1 2024; R&D expenses fell to $5.8M.
- Cash and equivalents $40M as of March 31, 2025; includes $11M from Feb 2025 registered direct offering with warrants for up to $11M more.
- VERSATILE-003 Phase 3 trial initiated for Versamune HPV + pembrolizumab in HPV16-positive HNSCC; targets ~350 patients with 2:1 randomization.
- FDA cleared IND for Versamune MUC1 + PDS01ADC in metastatic colorectal cancer; NCI to lead Phase 1/2 under CRADA.
- Three Versamune HPV abstracts selected for presentation at 2025 ASCO Annual Meeting (May 30-June 3).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125018800/0001140361-25-018800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125018800/ef20048917_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-018800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer